Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Lead asset MORF-057 is a small-molecule inhibitor that is currently in Phase 2b trial for ulcerative colitis, with a readout expected in the first half of 2025. It recently initiated a Phase 2 study in Crohn’s disease. Also Read: Eli Lilly’s Alzheimer’s Therapy’s Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst. Goldman Sachs writes that Takeda Pharmaceutical Company Ltd’s (NYSE:TAK) Entyvio generated $5.3 billion ...